KGK Science – MJ Shareholders https://mjshareholders.com The Ultimate Marijuana Business Directory Mon, 26 Sep 2022 17:40:12 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.3 Wellbeing Subsidiary KGK Science Opens New Clinical Research Center to Reimagine a Healthier Future https://mjshareholders.com/wellbeing-subsidiary-kgk-science-opens-new-clinical-research-center-to-reimagine-a-healthier-future/ Mon, 26 Sep 2022 17:40:12 +0000 https://www.cannabisfn.com/?p=2963810

Ryan Allway

September 26th, 2022

News, Top News


New Clinical Facility in London, Ontario Accelerates Research and Innovation

VANCOUVER, British Columbia, September 26, 2022–(BUSINESS WIRE)–Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company“) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that its wholly owned subsidiary KGK Sciences Inc. (“KGK”) has opened their new Clinical Research Center in London, Ontario, with the aim to accelerate their clients’ research and drug development needs in the nutraceutical, cannabinoid, hemp and psychedelic space.

KGK will host a grand opening ceremony on September 29, 2022 to officially open the new, state-of-the-art clinical research facility and celebrate being a leading contract research organization for over 25 years. The Company’s clinical research center empowers KGK to provide high-quality clinical research trials and expert regulatory support for clients in the nutraceutical, cannabis, hemp and psychedelic industries.

As a premium full-service contract research organization, KGK is dedicated to providing clinical trial research that meets the highest quality standards. Led by a team of scientific research and regulatory experts, KGK combines cutting-edge clinical science with industry expertise to design clinical trial and claim substantiation strategies customized to meet the needs of our clients. Having over 150 publications, the company is continuously pushing study designs and measurement tools forward in the industry and were most recently published in Frontiers Journal speaking about the assessment and re-evaluation of clinical trial design. The full article can be found here: Breaking new frontiers: Assessment and re-evaluation of clinical trial design for nutraceuticals.

“Our new research center, located in the heart of London, Ontario will draw upon the strength and heritage of applied research and innovation and will be an ongoing opportunity for ground-breaking research in the fields of nutraceuticals, cannabinoids, hemp and psychedelics with global partners, clients and academics, striving for excellence as we have done over the past 25 years,” said Najla Guthrie, CEO of Wellbeing & KGK. “Our goal is to strengthen the fundamental research needed for global innovation and enable the creation of next-generation nutraceuticals and pharmaceuticals.”

Media interested in attending the opening should contact Natalie Dolphin (email: [email protected]; phone: 416-706-6364) by 12 p.m. ET on Thursday, September 29, 2022.

ABOUT KGK SCIENCE

Subsidiary of Wellbeing Digital Sciences, KGK is a leading North American contract research organization based in London, Ontario that primarily provides high-quality clinical research trials with a focus on nutraceutical and emerging health care products. Founded in 1997, the business has successfully helped hundreds of companies with custom designed clinical trials and claim substantiation strategies to move products into global markets. KGK’s other existing service lines include expert regulatory support and compliance solutions, participant recruitment, research support services and consulting services. Furthermore, the company has produced over 150 publications, executed over 400 clinical trials across more than 40 indications, amassed 25,000 participants in its database and collected 10 million data points. For additional information, please visit kgkscience.com.

ABOUT WELLBEING DIGITAL SCIENCES

Wellbeing Digital Sciences Inc. is an evidence-based mental healthcare company focused on the development and implementation of innovative clinical treatment solutions, including psychedelic medicine and digital therapeutics, as supported by clinical research. Its mission is supported by a network of North American clinics that provide forward-thinking therapies and other types of treatment to patients as well as through a contract research organization that offers clinical trials services to clients pursuing drug development. For additional information, please visit wellbeingdigital.co.

On behalf of:
Najla Guthrie
Chief Executive Officer
WELLBEING DIGITAL SCIENCES

Notice Regarding Forward-Looking Information:

This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and prospects of the Company.

The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220926005255/en/

Contacts

For further information, please contact:
Natalie Dolphin
VP of Marketing & Investment Relations
Email: [email protected]
Twitter: @Wellbeing_IR

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
/R E P E A T – Nova Mentis and KGK Science Form Tactical Partnership/ https://mjshareholders.com/r-e-p-e-a-t-nova-mentis-and-kgk-science-form-tactical-partnership/ Thu, 27 Jan 2022 16:23:35 +0000 https://www.cannabisfn.com/?p=2936765

Ryan Allway

January 27th, 2022


The Companies Plan to Jointly Submit a Psilocybin Clinical Trial Application to Health Canada

VANCOUVER, BCJan. 27, 2022 /CNW/ – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is proud to announce that the Company has formed a tactical partnership with KGK Science Inc. (“KGK”), which is a wholly owned subsidiary of Wellbeing Digital Sciences Inc. (NEO: MEDI), to develop its psychedelic psilocybin drug portfolio in Canada. KGK is a leading North American contract research organization based in London, Ontario that primarily provides high-quality clinical research trials with a focus on the nutraceutical, cannabis and emerging psychedelic industries. Both Companies plan to jointly submit a clinical trial application (“CTA”) to Health Canada for a Phase 2A clinical study evaluating psilocybin microdose therapy for fragile X syndrome.

“NOVA and KGK have synergistic capabilities that will facilitate submission of the CTA to Health Canada and achieve, in my opinion, no objection to this unprecedented clinical study,” stated Dr. Marvin S. Hausman MD, Chairman of NOVA’s Scientific Advisory Board. “In our discussions with KGK, we realized early on that our two teams had the ability to navigate the entire lifecycle journey of our novel psilocybin microdose treatment of fragile X syndrome from a Phase 2A clinical study to drug approval and commercialization.”

“I am delighted to work with NOVA’s team to advance this novel initiative. NOVA’s microdose approach aims to address an unmet need that promises to have a significant impact on the lives of families impacted by fragile X syndrome. KGK is proud to be able to contribute and is confident our expertise will guide NOVA to success through the orphan drug pathway,” said Najla Guthrie, President and CEO of KGK.

NOVA’s research and clinical team initially identified unique opportunities in psychedelic drug development and chose a classic drug development pathway involving careful planning and execution of chemistry, manufacturing and preclinical proof of efficacy studies. The Company’s successes to date include but are not limited to:

  • NOVA is the first biotech company to achieve psilocybin orphan drug designation in both the United States and European Union;
  • Manufactured a large supply of >98% pure psilocybin for clinical studies and commercialization after drug approval;
  • Proof of efficacy and safety in preclinical rat models of autism spectrum disorder (ASD) and fragile X syndrome (FXS); 4 studies completed;
  • Established psilocybin microdose levels to treat FXS; and
  • Preparing Phase 2 chemistry and manufacturing file for regulatory submission.

KGK’s expertise includes:

  • Regulatory submission expertise;
  • Manage Investigational New Drug (“IND”) enabling activities;
  • Clinical trial design and trial execution;
  • Established clinical sites; and
  • In-house virtual behavioural testing models.

About KGK Science

Founded in 1997, KGK is a leading North American contract research organization based in London, Ontario that primarily provides high-quality clinical research trials with a focus on the nutraceutical, cannabis and emerging psychedelic industries. The business has successfully helped hundreds of companies with custom-designed clinical trials and claim substantiation strategies to move products into global markets. KGK’s other existing service lines include expert regulatory support and compliance solutions, participant recruitment, research support services and consulting services. On an approximate basis, the business to date has produced 150 publications, executed over 400 clinical trials across more than 40 indications, amassed 25,000 participants in its database and collected 10 million data points.

About Wellbeing Digital Sciences

Wellbeing Digital Sciences Inc. (formerly KetamineOne Capital Limited) is an evidence-based healthcare company focused on innovative clinical solutions, artificial intelligence-powered digital therapeutics and contract research. Its mission is supported by a network of North American clinics that provide ketamine-assisted therapies and other types of treatment to patients as well as through a contract research organization that offer clinical trials services to clients pursuing drug development. In essence, the company exists to make breakthrough treatments more accessible and to offer patients transformational experiences.

About Nova Mentis Life Science Corp.

Nova Mentis Life Science Corp. is a Canadian-based biotechnology company and global leader in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova is the first biotech company to achieve psilocybin orphan drug designation in both the United States and European Union.

The goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder (ASD) and Fragile X Syndrome (FXS).

For further information on the Company, please visit www.novamentis.ca.

On Behalf of the Board

Will Rascan, President & CEO
Nova Mentis Life Science Corp.

Phone: 778-819-0244
Toll Free: 1-833-542-5323
Twitter: @novamentislsc
Instagram: @novamentislsc
Facebook: @novamentislsc

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian
Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains statements that constitute “forward-looking statements.” Such forward looking statements
involve known and unknown risks, uncertainties and other factors that may cause Nova Mentis Life Science’s actual results,
performance or achievements, or developments in the industry to differ materially from the anticipated results, performance
or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that
are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,”
“intends,” “estimates,” “projects,” “potential” and similar expressions, or that events or conditions “will,” “would,” “may,”
“could” or “should” occur.

SOURCE Nova Mentis Life Science Corp.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>